The induction of dissociative states: A meta-analysis

Benjamin Brake, BSc[a,*], Lillian Wieder, MSc[b,*], Natasha Hughes, MSc[c,*], Ivonne Saravia Lalinde, MSc[d,*], Danielle Marr, MSc[e], Dali Geagea, MSc[f], Susannah Pick, PhD[g], Antje A. T. S. Reinders, PhD[g], Sunjeev K. Kamboj, PhD[h], Trevor Thompson, PhD [i], & Devin B. Terhune, PhD [d]

[a] *Department of Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College London*
[b] *Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's College London*
[c] *Department of Clinical Psychology, Leiden University, the Netherlands*
[d] *Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London*
[e] *Institute for Psychology, Friedrich Alexander Universität Erlangen-Nuremberg, Germany*
[f] *Centre for Children's Burns and Trauma Research, The University of Queensland, Brisbane, Australia*
[g] *Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London*
[h] *Clinical Psychopharmacology Unit, Department of Clinical, Educational and Health Psychology, University College London*
[i] *School of Human Sciences, University of Greenwich*

[*] These authors contributed equally to the manuscript.

Correspondence address:
Devin B. Terhune
Department of Psychology
Institute of Psychiatry, Psychology & Neuroscience (IOPPN)
King's College London
Henry Wellcome Building
Denmark Hill Campus
16 De Crespigny Park
London, UK SE5 8AB
devin.terhune@kcl.ac.uk

Acknowledgements: LW is supported by the Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's College London. SP is supported by a Medical Research Council Fellowship. SKK is supported by the Medical Research Council (UK). DBT is supported by the Gyllenbergs Foundation.

Financial disclosures: All authors have nothing to declare.

Contributors
All authors conceived the project. BB, LW, NH, ISL, DM, and DG carried out the database searches and data coding with assistance from SKK, TT and DBT. BB, LW, NH, ISL and DBT performed the meta-analysis with assistance from SP, AATSR, SKK, and TT. JB and TT. BB, LW, NH, ISL and DBT drafted the initial manuscript. All authors reviewed and approved the final version of the manuscript.

Competing interests
No, there are no competing interests for any author

Archived version
A version of this paper was previous uploaded to MedRxiv: t.ly/4XZZ4

Abstract

Objective: Dissociative states, characterised by discontinuities in awareness and perception, occur in a

diverse array of psychiatric disorders and contexts. Dissociative states have been experimentally modelled in

the laboratory through various induction methods but relatively little is known about the efficacy and

comparability of different experimental methods.

Methods: This meta-analysis quantified dissociative states, as indexed by a standardised instrument

(*Clinician Administered Dissociative States Scale*), at baseline in varied diagnostic categories and in

response to different experimental induction methods (psychological techniques and pharmacological

agents) in both clinical and non-clinical samples. Primary outcomes were state dissociation effect sizes

(Hedges's *g*) (PROSPERO registration CRD42022384886).

Results: 2,214 papers were screened, yielding 123 eligible articles and 155 effect sizes comprising 6,692

individuals. High levels of baseline state dissociation were observed in multiple diagnostic categories

relative to controls, with the largest effects found in the dissociative and complex subtypes of post-traumatic

stress disorder (PTSD-DC). In controlled experiments, induced state dissociation was most pronounced in

response to mirror-gazing and multiple pharmacological agents with effects exceeding baseline state

dissociation in PTSD-DC in ketamine and cannabis. The effect sizes were characterised by pronounced

heterogeneity but were not reliably associated with methodological features of the original studies.

Conclusions: Elevated state dissociation is present in multiple diagnostic categories and comparable or

higher levels can be reliably induced in controlled experiments using psychological techniques and

pharmacological agents. These results demonstrate the efficacy of several methods for experimentally

modelling dissociation and have implications for measuring adverse events and predicting outcomes in

clinical interventions involving pharmacological agents.

Keywords: dissociative; ketamine; mirror-gazing; NMDAR; psychedelics; PTSD

Introduction

Dissociation comprises a constellation of symptoms characterised by discontinuities in awareness, volition,

and perception (1, 2). These experiences range from episodes of depersonalisation and derealisation,

encompassing feelings of detachment from emotional or bodily states, and/or one's environment,

respectively, to distortions in control, identity and memory. Dissociation is increasingly recognised as a

transdiagnostic symptom prevalent in a wide variety of psychiatric conditions (2). Elevated levels of

dissociation may also serve as a salient marker of clinical outcomes including a higher burden of illness (3),

poorer quality of life (4), more pronounced symptomatology (5-7), and poorer treatment outcomes (8).

The clinical significance of dissociation underscores the need for controlled research on these symptoms

but there exists no consensus experimental model of dissociation. Psychological techniques range from those

that induce dissociative states through modulation of awareness and perception (e.g., mirror-gazing) or

exposure to stressors (9). Multiple pharmacological agents have been shown to trigger dissociation,

particularly those that function as N-methyl-D-aspartate receptor (NMDAR) antagonists, such as ketamine

and nitrous oxide (N_2O) (10). To our knowledge, there has not yet been any attempt to quantitatively

synthesise and contrast these different induction effects, nor to compare them against baseline dissociative

states in diagnostic categories.

A robust experimental model of dissociative states will offer novel opportunities for identifying

neurophysiological and neurochemical markers of dissociative states, elucidating the impact of dissociation

on other symptoms (e.g., hallucinations), and could inform both the diagnosis and treatment of a range of

psychiatric conditions (10, 11). Moreover, as NMDAR antagonists and serotonergic psychedelics are used or

proposed as mainstream antidepressants (12), studying their dissociative effects might aid in advancing

understanding of treatment-related adverse events (13) and treatment outcomes (14), which often covary

with dissociative responses.

This meta-analysis sought to fill outstanding gaps in current knowledge regarding the experimental

induction of dissociative states and their comparability to baseline dissociation in diagnostic categories. As

in other meta-analyses (2), we sought to increase uniformity of comparisons within and across categories

and thus restricted our analyses to studies that measured dissociative states using the *Clinician-Administered*

Dissociative States Scale (CADSS) (15), the most widely used measure of state dissociation (16). Our

primary aims were to quantitatively synthesise and compare baseline state dissociation effects in different

diagnostic categories and in induced state dissociation effects in response to different psychological

techniques and pharmacological agents. Our secondary aims were to explore the factors that moderate the

magnitude of state dissociation effects within and across categories.

Method

This pre-registered study (t.ly/I-ppg) was conducted under the updated PRISMA 2020 guidelines (17).

Eligibility criteria

The inclusion criteria were: English language; full article in a peer-reviewed journal; participants aged 18 or

older; inclusion of descriptive statistics and sample sizes for the CADSS in a diagnostic group and non-

clinical control group or in an experimental and control condition. Exclusion criteria included: reviews,

abstracts, dissertations, or case studies; data overlapping with included studies; use of a dissociation-

attenuating agent; and CADSS completion after an extended period (>12h).

Search strategy

In October 2022, two researchers (BB and LW) independently searched MEDLINE, PubMed, PsycINFO,

and Embase using terms relating to the CADSS (Supplementary Materials). The search was limited to

studies published since 1998, the CADSS's initial publication year. All eligible studies were integrated into a

database using Covidence ® (Veritas Health Innovation, Melbourne, Australia; available at

www.covidence.org). The search was repeated in June 2023 and March 2024, yielding 6 and 4 additional

studies, respectively.

Study selection

Two independent raters (BB, DG, NH, DM, ISL, LW) independently screened and assessed all studies for

eligibility using a two-stage procedure. First, they screened titles and abstracts, rejecting articles not meeting

eligibility criteria. Then, they reviewed the remaining papers to finalize the study list. A third reviewer

(DBT) resolved discrepancies at either stage. If eligible articles lacked sufficient CADSS data,

corresponding authors were contacted via email (up to three attempts over three months).

Data extraction

Data extraction was performed by two raters (BB, DG, NH, DM, ISL, LW). The primary outcomes extracted

were CADSS scores (15) in a target condition/group and a control condition/group. Secondary outcomes

included CADSS subscale scores and correlations between trait dissociation scores and CADSS scores. Both

raters independently extracted and coded data using a pre-piloted extraction form in Covidence, covering:

study details (authors, title, journal, publication date, country); demographics (sample size, gender

distributions, age, education, ethnicity); study design (repeated-measures, between-groups, mixed-model);

category (diagnostic group, psychological technique, pharmacological agent); CADSS information

(administrator [clinician/experimenter v. self-report], mode of administration [in person or remote], version

[number of items], number of measurement timepoints, subscales, language); trait dissociation measure;

clinical study methods (diagnosis, diagnostic criteria, diagnostic method, comorbidities, control type

[healthy or clinical], clinical control diagnosis); pharmacological study methods (CADSS measurement

times, drug class, dose, administration method and duration, concurrent drug-use information, active/inert

placebo information); psychological technique (method, control condition/group information); other

methodological details (counterbalancing, inclusion of suggestion for dissociation); descriptive statistics for

CADSS scores (total and subscales in all conditions); and correlations between trait dissociation and

CADSS scores. If descriptive statistics were not reported, they were extracted from figures using

WebPlotDigitizer (v. 4.6; https://automeris.io/) when possible. Discrepancies were resolved with a third

reviewer and sometimes a fourth. Overall, there was 91% agreement between raters (range: 85-98%).

Methodological quality

Two raters independently assessed the quality of each study using a 15-item scale (Supplementary

Materials) concerning study objectives, participant recruitment, demographic data, inclusion/exclusion

criteria, clarity of procedure, blinding, pre-registration, and relative matching of groups/conditions. The

items, adapted from a previous meta-analysis (18), were based on Cochrane criteria and PRISMA

recommendations (19). Each item was categorically rated (0=criterion not met, 1=met), and a percentage

met total was computed for each study; DBT resolved discrepancies. There was 90% agreement between

raters (range: 63%-100%; mean kappa=.80; range: .25-1).

Meta-analysis and meta-regression

Descriptive statistics (*M*s, *SD*s, and *n*s, or other suitable statistics) were used to compute Hedges's *g*s (and

*SE*s) for inclusion in random effects meta-analyses when there were three or more effect sizes per category

(Supplementary Methods). Multiple effect sizes were extracted and included in meta-analyses for specific

categories only when data from distinct samples were reported (see Supplementary Table 2). For studies that

reported multiple timepoints for the same participants (e.g., ketamine studies), we included only the effect

size corresponding to the peak response. Some categories had an insufficient number of effect sizes and

were thus consolidated into higher-order categories. Categories included different diagnostic categories,

psychological techniques, and pharmacological agents. For each category, we computed standardised mean

differences (*SMD*s) and 95% confidence intervals (CIs) after outlier removal (studentized residuals > |3.3|

(20)). Although analysis of raw CADSS scores could permit a clearer comparison of effect sizes across

categories, this approach was not feasible due to variations in the versions of the CADSS used by different

author groups, which differ in both the included items and of scores (16). *SMD*s were coded such that

positive values reflect greater state dissociation (CADSS score) in the reference category than a control.

Meta-analyses were supplemented with prediction intervals (PIs) when $k \geq 5$ (21, 22); PIs estimate the

distribution of the effect in a future individual study with similar features. Heterogeneity of effect sizes was

computed using I^2 and τ^2 where values exceeding 50% and 10%, respectively, reflect moderate or greater

heterogeneity. Publication bias was evaluated using funnel plots of *SMD*s against *SE*s and Egger's bias test,

where *p*<.05 reflects asymmetry (23); we computed revised *SMD*s correcting for asymmetry using the trim-

and-fill method (24). Moderators of effect sizes were assessed using meta-regression analyses where there

were at least five effects sizes in each category and at least 10 effect sizes within a category, respectively.

Multiple pre-registered analyses were not performed due to insufficient number of effect sizes or insufficient

information in original papers (Supplementary Materials). Analyses were performed in JASP (v. 0.18.3,

2014; JASP Team, the Netherlands), Jamovi (v. 2.3.26.0, the Jamovi project), and MATLAB (v. 2023a,

MathWorks, Natick, Massachusetts, USA).

The induction of dissociative states: A meta-analysis

Results

Study inclusion and characteristics

A PRISMA diagram showing study selection is presented in Supplementary Figure 1. 123 papers met

inclusion criteria, yielding 155 effect sizes (n=6,629) that could be included in our main analysis categories

(see Supplementary Results for exclusions). After excluding 9 outliers, the effect sizes included controlled

comparisons of diagnostic categories (k=32, n=1,729), psychological techniques (k=50, n=2,400), or

pharmacological agents (k=64, n=2,563) (Table 1). The largest categories (ks≥10) included PTSD, mirror-

gazing, trauma stimuli exposure, and ketamine. Methodological quality ratings and study details can be

found in Supplementary Table 2.

Table 1. Results of meta-analyses of state dissociation effects (CADSS scores in reference vs. control) as a

function of diagnostic category, psychological technique, and pharmacological agent.

Category	k	n	SMD	95% CI	PIs	Z	p	I^2 (%)	T^2	FPAp	Outliers
Diagnostic categories											
PTSD-DC	7	443	1.34	[0.86, 1.82]	[-0.23, 2.91]	5.44	<.001	78.77	.31	.013	0
PTSD	12	644	0.94	[0.65, 1.23]	[0.04, 1.84]	6.42	<.001	61.66	.14	.030	0
MDD	6	338	0.89	[0.43, 1.35]	[-0.63, 2.41]	3.82	<.001	75.27	.24	.77	0
SZ	3	146	0.86	[0.51, 1.21]	[-1.49, 3.21]	4.83	<.001	0	0	.34	0
FND	4	158	0.59	[-0.17, 1.35]	[-2.84, 4.02]	1.52	.13	80.59	.48	.086	0
Psychological techniques											
Mirror-gazing	12	392	0.94	[0.52, 1.35]	[-0.63, 2.51]	4.44	<.001	86.43	.45	<.001	0
Military training	9	639	0.77	[0.52, 1.02]	[-0.07, 1.61]	6.10	<.001	80.1	.11	.37	1
Sleep deprivation	3	110	0.56	[0.26, 0.86]	[-2.69, 3.81]	3.69	<.001	52.2	.04	.063	1
Trauma stimuli	18	902	0.50	[0.36, 0.64]	[-0.01, 1.00]	6.94	<.001	63.68	.05	.15	1
Complementary methods	3	232	0.41	[0.14, 0.67]	[-1.76, 2.58]	2.99	.003	22.29	.01	.23	0
Negative affect stimuli	5	125	0.16	[-0.02, 0.34]	[-0.15, 0.47]	1.79	.074	0	0	.20	1
Pharmacological agents											
Ketamine	47	1,579	1.51	[1.23, 1.80]	[0.17, 2.85]	13.70	<.001	83.65	.42	<.001	4
Cannabis	4	139	1.40	[0.96, 1.83]	[-1.39, 4.19]	6.30	<.001	72.76	.37	.002	0
N_2O	3	129	1.16	[0.91, 1.41]	[-0.53, 2.85]	9.00	<.001	0	0	.42	0
Psychedelics	4	68	1.16	[0.66, 1.67]	[-0.91, 3.23]	4.50	<.001	63.03	.16	.34	1
Esketamine	6	648	0.94	[0.55, 1.33]	[-0.28, 2.16]	4.77	<.001	78.87	.15	.001	0

Notes. k = number of included effect sizes (after removal of outliers); N = sample size; SMD = standardized mean difference; PIs = prediction intervals; I^2 = heterogeneity statistic; T^2 = heterogeneity statistic; FPAp = funnel plot asymmetry p-value; outliers = number of outliers removed; FND = functional neurological disorder; MDD = major depressive disorder; N_2O = nitrous oxide; PTSD = post-traumatic stress disorder; PTSD-DC = post-traumatic stress disorder - dissociative subtypes and complex subtypes; SZ = schizophrenia.

Meta-analyses of controlled comparisons of state dissociation in diagnostic categories

The magnitude of state dissociation at baseline was examined in five diagnostic groups in order to provide a

reference point for effect sizes for induced dissociative states (Table 1, Figure 1). Dissociative states were

significantly greater than non-clinical controls in all groups except functional neurological disorder (FND).

Baseline state dissociation was most pronounced in patients meeting criteria for the dissociative and

complex subtypes of PTSD (PTSD-DC) (*SMD*=1.34; Figure 2), followed by weaker, yet still large, effects in

PTSD, MDD, and schizophrenia, which displayed comparable effect sizes (analyses of CADSS subscales

were not possible due to an insufficient number of studies) (for forest plots, see Supplementary Materials).

Prediction intervals were only significant in PTSD whereas moderate-to-large heterogeneity was observed in

all groups except schizophrenia.

12
Figure 1. Results of meta-analyses of state dissociation (CADSS scores) at baseline in diagnostic
categories (red), in response to psychological interventions (green), and in response to pharmacological
agents (blue). CADSS = clinician administered dissociative states scale; SMD=Standardised Mean
Difference; FND = functional neurological disorder; SZ = schizophrenia; MDD = major depressive disorder;
PTSD = post-traumatic stress disorder; PTSD-DC = PTSD dissociative and complex subtypes; N_2O =
nitrous oxide.
19

Figure 2. Forest plot of *Standardised Mean Differences* (*SMD*s; with 95% Confidence Intervals [CIs]) of baseline state dissociation (CADSS scores) in post-traumatic stress disorder dissociative and complex subtypes (PTSD-DC) relative to controls. Marker sizes reflect study weights with smaller markers denoting smaller study weights.

Meta-analyses of psychological techniques for the induction of dissociative states

All induction methods significantly increased state dissociation except negative affect stimuli exposure

(Table 1, Figure 1). Mirror-gazing was associated with a large effect size (*SMD*=0.94; see Figure 3),

followed by a large effect for military training whereas sleep deprivation, trauma stimuli exposure, and

complementary methods elicited moderate effects (for forest plots, see Supplementary Materials). Prediction

intervals were non-significant for all methods. Moderate-to-large heterogeneity in effect sizes was observed

for mirror-gazing, military training, and trauma stimuli exposure. Further analyses suggested that the effects

of mirror-gazing were most pronounced for derealisation (Supplementary Table 3).

Figure 3. Forest plot of *Standardised Mean Differences* (*SMD*s; with 95% Confidence Intervals [CIs]) of induced state dissociation (CADSS scores) in response to mirror-gazing relative to a control condition. Marker sizes reflect study weights with smaller markers denoting smaller study weights.

Meta-analyses of pharmacological induction of dissociative states

The analyses of pharmacological agents revealed that all agents reliably induced dissociative states with

large effect sizes (Table 1, Figure 1, for forest plots, see Supplementary Materials). The largest effect sizes

were observed for ketamine (Figure 4) and cannabis (*SMD*s>1.35), with slightly weaker effects for N_2O and

psychedelics (*SMD*s=1.16) and the weakest, albeit still large, effect for esketamine. Prediction intervals were

significant only for ketamine and moderate-to-large heterogeneity in effect sizes was observed for all agents

except N_2O. Analyses of subdimensions of dissociation yielded comparable results although the effects were

generally larger for derealisation across all agents (see Supplementary Table 3). Further analyses suggested

that the dissociative effects were most pronounced during the first 30 minutes post-infusion (see

Supplementary Table 4).

Figure 4. Forest plot of *Standardised Mean Differences* (*SMDs*; with 95% Confidence Intervals [CIs]) of

induced state dissociation (CADSS scores) in response to ketamine relative to a control condition. Marker

sizes reflect study weights with smaller markers denoting smaller study weights.

Publication bias

Among diagnostic categories and psychological techniques, the effect sizes for PTSD-DC, PTSD, and

mirror-gazing showed significant evidence of funnel plot asymmetry (see Table 1 and Supplementary

Materials for funnel plots). By contrast, significant funnel plot asymmetry was observed for all

pharmacological agents except N_2O and psychedelics. These results are potentially reflective of potential

publication bias and suggest that effect size estimates for multiple categories may be inflated.

Meta-regressions

Meta-regression analyses were undertaken to examine whether variability in effect sizes across studies was

attributable to different methodological features across studies including the induction method,

administration method, sample, design, and other methodological features. Our first set of meta-regression

analyses compared state dissociation effects across categories in cases where $k \geq 5$ in each category

(Supplementary Table 5). Both mirror-gazing and military training elicited larger increases in state

dissociation than exposure to trauma and negative affect stimuli (ΔSMDs>0.30), but the former two did not

significantly differ. By contrast, no significant differences were found across diagnostic categories or

pharmacological agents. Baseline dissociation in PTSD-DC was greater than induced dissociation for all

induction methods (ΔSMDs>0.50) except for mirror-gazing and pharmacological agents. Baseline

dissociation in PTSD and MDD was greater than induced effects from trauma and negative affective stimuli

exposure but weaker than pharmacological induction effects. Finally, comparisons across categories

indicated that induced dissociation was greater in response to ketamine than all psychological techniques

(ΔSMDs>0.50) whereas the response to esketamine was only greater relative to trauma and negative

affective stimuli exposure.

Our final set of meta-regression analyses sought to clarify whether heterogeneity in effect sizes is

associated with different methodological features (Supplementary Table 6). Effect sizes were not

significantly moderated by methodological quality or administration method (clinician/experimenter vs. self-

report). Non-clinical samples displayed a stronger dissociative response to ketamine than clinical samples

(ΔSMD=0.46), but the two groups did not significantly differ in other categories. Experimental design did

not uniformly significantly moderate effect sizes with larger induction effects for between-groups designs

and within-groups designs for mirror-gazing and ketamine, respectively. Induction effects did not differ

across different types of control conditions for psychological techniques whereas among ketamine studies

effect sizes were greater in studies employing inert placebo controls than baseline or active drug controls but

were not significantly moderated by dose or route of administration.

Discussion

This meta-analysis sought to quantify, and compare, baseline state dissociation effects in clinical samples

and induced state dissociation effects in response to psychological techniques and pharmacological agents.

Baseline state dissociation was elevated in multiple diagnostic categories relative to controls but was most

pronounced in individuals with PTSD dissociative and complex subtypes (PTSD-DC). Among induction

studies, multiple pharmacological agents elicited pronounced dissociative effects in clinical and non-clinical

samples. Mirror-gazing was the most robust psychological technique, closely approximating the dissociative

effects of pharmacological agents. These results reinforce state dissociation as a prominent transdiagnostic

symptom (2) and demonstrate clinically-significant dissociative states can be reliably induced using a range

of methods (9, 10).

Our analyses confirmed the presence of elevated baseline state dissociation across several diagnostic

categories. Baseline dissociation was most pronounced in PTD-DC and PTSD, although most studies did not

distinguish between PTSD subgroups. Elevated state dissociation in these groups broadly aligns with

previous analyses of *trait* dissociation (2), although our results diverge from the latter analysis insofar as

individuals with schizophrenia and depressive disorders displayed comparable, albeit weaker, dissociative

effects to PTSD in our analysis. Moreover, whereas individuals with FND have been shown to display high

levels of trait dissociation, comparable to PTSD (2, 5), FND was characterised by only moderate levels of

state dissociation in our analyses and was the only non-significant diagnostic category. This discrepancy is

plausibly attributable to a small number of studies including FND samples and the greatest heterogeneity

among all diagnostic categories likely driven by differential levels of dissociation in FND subgroups (5).

Although state and trait dissociation are strongly associated, they should be distinguished in research and

clinical practice, as state dissociation may indicate more severe psychopathology (25). These results

reinforce the importance of measuring dissociation in different diagnostic categories and clinical contexts,

particularly given that dissociation may predict broader symptomatology (5-7), and treatment outcomes (26).

Analyses of pharmacological agents revealed that two agents elicited state dissociation effects that were

comparable to, or exceeded, baseline dissociation in individuals with PTSD-DC. The most pronounced

effects were observed with ketamine and cannabis, with slightly weaker, albeit still large, effects in N_2O and

psychedelics, and esketamine. Further analyses suggested that ketamine's dissociative effects are greatest

the first 50 minutes post-infusion and larger in non-clinical samples. Taken together, these results indicate

that different types of pharmacological action can produce large dissociative effects. Accordingly,

dissociative states might not be associated with the perturbation of a specific neurochemical system but

rather with broader network-level increases in neural signal complexity and changes in intra- and inter-

network connectivity that are shared across these agents (27, 28) and potentially with clinical samples (29)

(for a consideration of neurophysiological differences across some of these agents, see (30)). For example,

ketamine, N_2O, and LSD are all associated with aberrant functional connectivity in nodes of the default

mode and dorsal attention networks (e.g., precuneus and temporoparietal junction) (28), which may parallel

atypical precuneus and temporoparietal volume and/or functional connectivity in individuals with high

dissociation (31-34). These effects may reflect disruptions in embodiment and multimodal integration that

play a central role in experiences of depersonalisation and derealisation or distortions in features of

subjective experience subserved by a broader posterior cortical hot zone, which is hypothesised to play a

critical role in supporting the subjective contents of consciousness (28). Continued research into these other

compounds may also help in advancing research into pharmacotherapeutic agents for dissociative

symptomatology; for example, whereas N_2O acts a partial agonist of opioid receptors (30), preliminary

research suggests that opioid antagonists seem to reduce dissociative symptoms (35) (see also (36)).

Among psychological techniques for inducing dissociative states, mirror-gazing was the only method

that elicited comparable dissociative effects to those observed in diagnostic categories and with

pharmacological agents. In particular, the magnitude of the dissociative response to mirror-gazing was

similar to baseline dissociation in PTSD (and larger than all categories except PTSD-DC) and induced

dissociation in response to esketamine but weaker than all other pharmacological agents. The neurocognitive

substrates of mirror-gazing remain largely unknown but it may produce dissociative states, particularly

depersonalisation, through a partial decoupling of visual and cognitive self-referential processing (1, 37). By

contrast, stress induction methods used in military/survival training elicited weaker, albeit still large, effects

that were larger than moderate and non-significant effects for exposure to trauma stimuli and negative affect

stimuli, respectively. The greater efficacy of the former is plausibly attributable to its status as a more

uniform stressor than tasks involving different types of stimulus presentation with variable effects across

individuals. Techniques targeting awareness and attention (sleep deprivation, complementary methods) also

produced moderate dissociative effects, which aligns with accumulating evidence for a link between sleep

disturbances and dissociation (1) . Although typically viewed as a consequence of stress (1, 3), these results

cumulatively indicate that dissociative states can be reliably induced through a variety of methods including

by modulating awareness, perception, and sleep and highlight the need for direct comparisons of these

methods and their neurocognitive substrates (1, 9).

The observed state dissociation effects have direct implications for the development of an experimental

model of dissociation (38). The cumulative data point to the greater efficacy of mirror-gazing relative to

stress induction methods, given that it produces larger dissociative effects and is less likely to trigger

adverse events (9, 39). Our results additionally highlight ketamine, cannabis, and N_2O as the most robust

pharmacological agents for inducing dissociation; the latter is particularly well-suited to experimental

research given that its low blood solubility elicits rapid induction and termination effects (10, 39). Although

these results are not formally incompatible with broad consensus that dissociative psychopathology is a

consequence of developmental trauma (40), they underscore the need for direct comparisons between

methods. Preliminary research suggests that script-driven imagery methods of inducing dissociation seem to

be associated with activation patterns (e.g., greater amygdala activation (41)) that differ from those

involving pharmacological agents (28). Accordingly, further neurophysiological research comparing

different methods is necessary to understand the extent to which these methods have overlapping and

distinct neurocognitive substrates. Preliminary trends suggest that different pharmacological agents and

mirror-gazing produce greater derealisation than depersonalisation; further targeting these effects could be

beneficial in elucidating the neural correlates of subdimensions of dissociation (42). Development of

experimental models of dissociation will also require greater attention to the temporal dynamics of, and

dosing effects on, state dissociation, which are poorly understood apart from ketamine. Our analyses suggest

that clinical samples display weaker dissociative responses to ketamine and previous research points to trait

dissociation as a predictor of such responses (26); further attention to the sources of individual differences in

response to induction methods is necessary. Finally, although our meta-analysis demonstrates that mirror-

gazing and multiple pharmacological agents can induce dissociative states that are large in magnitude and

comparable to baseline dissociation in some clinical samples, further research is required to assess their

clinical relevance in comparison to dissociative effects in diagnostic categories.

Limitations

The principal limitations of this meta-analysis concern limited available data in specific categories and

methodological weaknesses in the original studies. Many categories included a small number of effect sizes,

thereby limiting the precision of our estimates and preventing us from examining sources of heterogeneity.

Our choice to restrict our analyses to studies using the CADSS facilitated comparisons across categories and

ensured a good degree of phenomenological uniformity in response patterns but may have excluded

important research with other validated instruments (16). In turn, it will be important for future empirical

studies and meta-analyses to compare and contrast the CADSS with these other measures. Only a small

proportion of studies reported CADSS subscale scores (e.g., depersonalisation) thereby limiting our analyses

of different subdimensions of state dissociation. It remains unclear whether this omission reflects publication

bias, poor psychometric properties of specific subscales, or other factors but further research into these

subscales and their psychometric properties and discriminant validity is required. Only a small minority of

studies included trait dissociation measures, which prevented us from assessing their value in predicting

dissociation induction effects (26). State dissociation was alternately measured *peri*-induction (most

pharmacological agents) or post-induction (most psychological techniques), which may introduce different

response biases that were not captured in our analyses. Relatedly, most of the original studies are potentially

confounded by demand characteristics and potential placebo effects as participants are likely to become

unblinded to experimental conditions due to psychoactive effects (43). We planned to probe this in our pre-

registered analyses by examining the presence of suggestions for dissociative responses during procedures,

but this information was not reliably reported and could not be analysed. Insofar as dissociation was

typically measured as a secondary outcome or adverse event (13), these types of biases may be less

pronounced than for psychedelic effects but further consideration of this issue is warranted, such as through

the use of active drug controls, stringent reporting of suggestion effects, and statistical corrections for

unblinding effects (44).

Aside from ketamine, studies did not report state dissociation at multiple time points, thereby

disenabling systematic analyses of peak dissociation effects. We were unable to examine the potential

confounding effects of concurrent psychotropic medication in clinical samples. Except for ketamine, we

were unable to examine the moderating impact of dose on state dissociation effects due to small sample

sizes. Moreover, most studies reported ketamine (and other agent) doses as mg/kg, which does not account

for individual differences in drug absorption, metabolism, distribution, and excretion (45), leading to

variability in plasma concentrations and dissociative effects that could not be captured in our ketamine dose

analyses. For this reason, our observation of a non-significant effect of ketamine dose on state dissociation

should be treated with caution. Many of the agents we analysed elicit broader psychotomimetic effects (e.g.,

hallucinations) that could overshadow more subtle dissociative responses (10, 12, 46), thereby potentially

limiting the measurement reliability of state dissociation (47).

Summary and conclusions

This meta-analysis confirmed that state dissociation is a transdiagnostic symptom present in multiple

psychiatric conditions that can be reliably induced using different pharmacological agents as well as mirror-

gazing. These findings have direct implications for the experimental modelling of dissociation in controlled

research, the search for neurophysiological markers of dissociation, and the assessment of adverse events

and treatment outcomes in psychopharmacological interventions involving NMDAR antagonists and classic

psychedelics.

References

1.   Lynn SJ, Polizzi C, Merckelbach H, Chiu CD, Maxwell R, van Heugten D, et al. (2022):

Dissociation and Dissociative Disorders Reconsidered: Beyond Sociocognitive and Trauma Models

Toward a Transtheoretical Framework. *Annu Rev Clin Psychol*. 18:259-289.

2.   Lyssenko L, Schmahl C, Bockhacker L, Vonderlin R, Bohus M, Kleindienst N (2018):

Dissociation in Psychiatric Disorders: A Meta-Analysis of Studies Using the Dissociative

Experiences Scale. *Am J Psychiatry*. 175:37-46.

3.   Lebois LAM, Harnett NG, van Rooij SJH, Ely TD, Jovanovic T, Bruce SE, et al. (2022):

Persistent Dissociation and Its Neural Correlates in Predicting Outcomes After Trauma Exposure.

Am J Psychiatry. 179:661-672.

4.   Polizzi CP, Aksen DE, Lynn SJ (2022): Quality of life, emotion regulation, and

dissociation: Evaluating unique relations in an undergraduate sample and probable PTSD

subsample. *Psychol Trauma*. 14:107-115.

5.   Campbell MC, Smakowski A, Rojas-Aguiluz M, Goldstein LH, Cardena E, Nicholson TR,

et al. (2022): Dissociation and its biological and clinical associations in functional neurological

disorder: systematic review and meta-analysis. *BJPsych Open*. 9:e2.

6.   Bloomfield MAP, Chang T, Woodl MJ, Lyons LM, Cheng Z, Bauer-Staeb C, et al. (2021):

Psychological processes mediating the association between developmental trauma and specific

psychotic symptoms in adults: a systematic review and meta-analysis. *World Psychiatry*. 20:107-

123.

7.   Longden E, Branitsky A, Moskowitz A, Berry K, Bucci S, Varese F (2020): The

Relationship Between Dissociation and Symptoms of Psychosis: A Meta-analysis. *Schizophr Bull*.

46:1104-1113.

8.   Bae H, Kim D, Park YC (2016): Dissociation predicts treatment response in eye-movement

desensitization and reprocessing for posttraumatic stress disorder. *J Trauma Dissociation*. 17:112-

130.

9.   Sleight FG, McDOnald, C. W., Mattson, R., Lynn, S. J. (2024): Inducing dissociative states:

A (re)view from the laboratory.

10.   Piazza GG, Iskandar G, Hennessy V, Zhao H, Walsh K, McDonnell J, et al. (2022):

Pharmacological modelling of dissociation and psychosis: an evaluation of the Clinician

Administered Dissociative States Scale and Psychotomimetic States Inventory during nitrous oxide

('laughing gas')-induced anomalous states. *Psychopharmacology (Berl)*. 239:2317-2329.

11.   Roydeva MI, Reinders A (2021): Biomarkers of Pathological Dissociation: A Systematic

Review. *Neurosci Biobehav Rev*. 123:120-202.

12.   Kalmoe MC, Janski AM, Zorumski CF, Nagele P, Palanca BJ, Conway CR (2020):

Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents.

J Neurol Sci. 412:116778.

13.   Short B, Fong J, Galvez V, Shelker W, Loo CK (2018): Side-effects associated with

ketamine use in depression: a systematic review. *Lancet Psychiatry*. 5:65-78.

14.   Johnston JN, Kadriu B, Allen J, Gilbert JR, Henter ID, Zarate CA, Jr. (2023): Ketamine and

serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting

antidepressant treatment. *Neuropharmacology*. 226:109422.

15.   Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, et al.

(1998): Measurement of dissociative states with the Clinician-Administered Dissociative States

Scale (CADSS). *J Trauma Stress*. 11:125-136.

16.   Wainipitapong S, Millman, L. S. M., Wieder, L., Terhune, D., Pick, S. (2024): Assessing

dissociation: a systematic review and evaluation of existing measures.

17.   Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. (2021):

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *J Clin*

Epidemiol. 134:178-189.

18.   Wieder L, Brown RJ, Thompson T, Terhune DB (2022): Hypnotic suggestibility in

dissociative and related disorders: A meta-analysis. *Neurosci Biobehav Rev*. 139:104751.

19.   Thompson T, Terhune DB, Oram C, Sharangparni J, Rouf R, Solmi M, et al. (2019): The

effectiveness of hypnosis for pain relief: A systematic review and meta-analysis of 85 controlled

experimental trials. *Neurosci Biobehav Rev*. 99:298-310.

20.   Viechtbauer W, Cheung MW (2010): Outlier and influence diagnostics for meta-analysis.

Res Synth Methods. 1:112-125.

21.   IntHout J, Ioannidis JP, Rovers MM, Goeman JJ (2016): Plea for routinely presenting

prediction intervals in meta-analysis. *BMJ Open*. 6:e010247.

22.   Riley RD, Higgins JP, Deeks JJ (2011): Interpretation of random effects meta-analyses.

BMJ. 342:d549.

23.   Egger M, Davey Smith G, Schneider M, Minder C (1997): Bias in meta-analysis detected

by a simple, graphical test. *BMJ*. 315:629-634.

24.   Duval S, Tweedie R (2000): Trim and fill: A simple funnel-plot-based method of testing

and adjusting for publication bias in meta-analysis. *Biometrics*. 56:455-463.

25.   Salmon AP, Nicol K, Kaess M, Jovev M, Betts JK, Chanen AM (2023): Associations of

state or trait dissociation with severity of psychopathology in young people with borderline

personality disorder. *Borderline Personal Disord Emot Dysregul*. 10:20.

26.   Niciu MJ, Shovestul BJ, Jaso BA, Farmer C, Luckenbaugh DA, Brutsche NE, et al. (2018):

Features of dissociation differentially predict antidepressant response to ketamine in treatment-

resistant depression. *J Affect Disord*. 232:310-315.

27.   Rajpal H, Mediano PAM, Rosas FE, Timmermann CB, Brugger S, Muthukumaraswamy S,

et al. (2022): Psychedelics and schizophrenia: Distinct alterations to Bayesian inference.

Neuroimage. 263:119624.

28.   Dai R, Larkin TE, Huang Z, Tarnal V, Picton P, Vlisides PE, et al. (2023): Classical and

non-classical psychedelic drugs induce common network changes in human cortex. *Neuroimage*.

273:120097.

29.   Lebois LAM, Li M, Baker JT, Wolff JD, Wang D, Lambros AM, et al. (2021): Large-Scale

Functional Brain Network Architecture Changes Associated With Trauma-Related Dissociation.

Am J Psychiatry. 178:165-173.

30. Breault MS, Orguc S, Kwon O, Kang GH, Tseng B, Schreier DR, et al. (2025): Anesthetics as Treatments for Depression: Clinical Insights and Underlying Mechanisms. *Annu Rev Neurosci*.

31. Rabellino D, Thome J, Densmore M, Theberge J, McKinnon MC, Lanius RA (2023): The Vestibulocerebellum and the Shattered Self: a Resting-State Functional Connectivity Study in Posttraumatic Stress Disorder and Its Dissociative Subtype. *Cerebellum*. 22:1083-1097.

32. Harricharan S, Nicholson AA, Thome J, Densmore M, McKinnon MC, Theberge J, et al. (2020): PTSD and its dissociative subtype through the lens of the insula: Anterior and posterior insula resting-state functional connectivity and its predictive validity using machine learning. *Psychophysiology*. 57:e13472.

33. Sierk A, Daniels JK, Manthey A, Kok JG, Leemans A, Gaebler M, et al. (2018): White matter network alterations in patients with depersonalization/derealization disorder. *J Psychiatry Neurosci*. 43:347-357.

34. Badura Brack AS, Marklin M, Embury CM, Picci G, Frenzel M, Klanecky Earl A, et al. (2022): Neurostructural brain imaging study of trait dissociation in healthy children. *BJPsych Open*. 8:e172.

35. Escamilla I, Juan N, Penalva C, Sanchez-Llorens M, Renau J, Benito A, et al. (2023): Treatment of dissociative symptoms with opioid antagonists: a systematic review. *Eur J Psychotraumatol*. 14:2265184.

36. Gitlin J, Chamadia S, Locascio JJ, Ethridge BR, Pedemonte JC, Hahm EY, et al. (2020): Dissociative and Analgesic Properties of Ketamine Are Independent. *Anesthesiology*. 133:1021-1028.

37. Mash J, Jenkinson PM, Dean CE, Laws KR (2023): Strange face illusions: A systematic review and quality analysis. *Conscious Cogn*. 109:103480.

38. Lynn SJ, Maxwell R, Merckelbach H, Lilienfeld SO, Kloet DVH, Miskovic V (2019): Dissociation and its disorders: Competing models, future directions, and a way forward. *Clin Psychol Rev*. 73:101755.

39. Collado V, Nicolas E, Faulks D, Hennequin M (2007): A review of the safety of 50%

nitrous oxide/oxygen in conscious sedation. *Expert Opin Drug Saf*. 6:559-571.

40. Dalenberg CJ, Brand BL, Gleaves DH, Dorahy MJ, Loewenstein RJ, Cardena E, et al.

(2012): Evaluation of the evidence for the trauma and fantasy models of dissociation. *Psychol Bull*.

138:550-588.

41. Mertens YL, Manthey A, Sierk A, Walter H, Daniels JK (2022): Neural correlates of acute

post-traumatic dissociation: a functional neuroimaging script-driven imagery study. *BJPsych Open*.

8:e109.

42. Hack LM, Zhang X, Heifets BD, Suppes T, van Roessel PJ, Yesavage JA, et al. (2023):

Ketamine's acute effects on negative brain states are mediated through distinct altered states of

consciousness in humans. *Nat Commun*. 14:6631.

43. Burke MJ, Blumberger DM (2021): Caution at psychiatry's psychedelic frontier. *Nat Med*.

27:1687-1688.

44. Szigeti B, Nutt D, Carhart-Harris R, Erritzoe D (2023): The difference between 'placebo

group' and 'placebo control': a case study in psychedelic microdosing. *Sci Rep*. 13:12107.

45. Hanks F, Phillips, B., Barton, G., Hakes, L., & McKenzie, C. (2022): How critical illness

impacts drug pharmacokinetics and pharmacodynamics. . *The Pharmaceutical Journal*. 308.

46. Ruffell SGD, Crosland-Wood M, Palmer R, Netzband N, Tsang W, Weiss B, et al. (2023):

Ayahuasca: A review of historical, pharmacological, and therapeutic aspects. *PCN Rep*. 2:e146.

47. Schwenk ES, Viscusi ER, Buvanendran A, Hurley RW, Wasan AD, Narouze S, et al.

(2018): Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain

Management From the American Society of Regional Anesthesia and Pain Medicine, the American

Academy of Pain Medicine, and the American Society of Anesthesiologists. *Reg Anesth Pain Med*.

43:456-466.

25